Windlas Biotech Limited — Investor Meet, 28-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Windlas Biotech reported strong Q4 and FY26 results. FY26 revenue grew 19% to INR904 Cr, with Q4 revenue up 18% to INR238 Cr. Adjusted PAT for FY26 was INR83 Cr (9.2%). CDMO revenue increased 20% YoY to INR664 Cr, and exports surged 40% to INR46 Cr. The injectables facility gained Philippines GMP approval, and Plant 6 is set for H1 FY27 commercialization. Management highlighted strong operating cash flows (INR105 Cr) and disciplined capital allocation, including a buyback and dividend. Trade generics faced a temporary dip from a codeine ban. The outlook is confident, focusing on growth, operational efficiencies, and quality systems.